Tango Therapeutics TNGX
$21.73 −$0.98 (-4.32%)
Market closed · Nov 22, 5:30 am ET · Last extended-hours $22.00 +1.24%
Open$22.11
Prev close$22.71
Day range$21.63 – $23.05
Volume1.74M
Market cap$3.68B
P/E (TTM)–
Dividend yield–
TNGX Stock News
Headlines matching Tango Therapeutics or the TNGX ticker, most recent first.
- Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $35
- CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46
- H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $68 Positive
- Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40
- Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $35 Positive
- Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)
- Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39 Positive
- J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46
- A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $42
- CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46 Positive
- Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60
- Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60 Positive
- CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42
- H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66
- A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66
No comments yet — be the first to weigh in on TNGX.
Sign in to join the discussion.